1. Introduction {#sec1}
===============

Natural products, especially from plants, are important medicinal source for many diseases as documented in *Charaka Samhita*, a comprehensive text on ancient Indian medicine written during 200--400 B.C., known as "*Encyclopedia of Ayurveda*" \[[@B1]\]. India is considered to be the botanical garden of the world. A wide variety of plants with an array of medicinal properties has been reported \[[@B2]\]. However, the medicinal value of these plants depends upon several ecological factors which include climatic factors like rainfall, atmospheric humidity, wind, gases, temperature, and light; physiographic factors (altitude and sunlight); and biotic and abiotic factors (soil microorganisms and nutrients) \[[@B3]\]. Moreover, such ecological factors varied based on different seasons and diverse geographical regions. Therefore, it is worthwhile to prepare a detailed document for the optimization of the conditions for the collection of plant material and in-depth investigation for the best utilization of such herbal product for a specific disease.

Accordingly, we have carefully selected an edible plant, *Murraya koenigii* (L.) Spreng, commonly called as "curry leaves" or "Kari patta or Karuveppilai or Karivepaku" abundantly available throughout India, for such documentation. This herb belongs to the family Rutaceae, leaves are pinnate, with 11--21 leaflets, and each leaflet is 2--4 cm long and 1--2 cm broad. This plant has been reported for its traditional uses like diarrhea, indigestion, and nausea in *Charaka Samhita* \[[@B1]\]. In the last ten years, we have isolated and extensively characterized a biologically active carbazole alkaloid (mahanine) from the leaflets of this plant and established its anticancer activity against different cancer cells with various mutations \[[@B4]\]. Our extensive study also ascertained its role in controlling several cell survival pathways in leukemia, pancreatic, ovarian, glioblastoma, cervical, and colon cancers. We also observed that mahanine is a pro-oxidant molecule. It induced death receptor-mediated apoptosis in leukemia, acts as mTORC1/2 inhibitor in glioblastoma multiform \[[@B5]\] and regulation of hedgehog pathway \[[@B6]\] and, acts as Hsp90 inhibitor in pancreatic \[[@B7]\] and enhanced tumor suppressor proteins in colon cancers, inhibited autophagy and LC3-mediated anoikis in ovarian cancer \[[@B8]\]. Additionally, it showed a good synergistic effect with clinically approved drugs both in colon and cervical cancers. It also exhibited antileishmanial activity through immunomodulation \[[@B9]\].

Accordingly, we aimed to prepare a mahanine-enriched fraction (MEF) from *Murraya koenigii* leaflets. In search of the highest mahanine-containing plant, we performed an elaborate, systemic detailed comparative study to understand the relationship of seasonal and geographical variations of other molecules present in MEF including mahanine in the leaflets of *M. koenigii* and compared their biological activities. Accordingly, we have collected the leaflets from all over India having different climatic conditions, altitude, and sunlight and soil properties throughout the year.

Here, we are reporting a two-step protocol for the preparation of MEFs using only two edible solvents from leaflets collected during different seasons throughout India. Next, we identified and characterized three carbazole alkaloids (mahanine, mahanimbine, and koenimbine) from MEF and compared their reduced metabolic activity against two representative ovarian cancer cell lines (PA1 and OVCAR3) at different concentrations. We found that mahanine content in the leaflet was more in the southern part of India during September--December, which is directly proportional to the highest biological activity *in vitro*. MEF also exhibited reduced tumor mass in ovarian, lung cancer xenograft mice. To our knowledge, it is the first report of systematic detailed study to determine the best place and season to collect *M. koenigii* leaflets with the highest medicinal values to elevate the commercial value of this high-demand plant.

2. Materials and Methods {#sec2}
========================

2.1. Cell Cultures {#sec2.1}
------------------

Human ovarian (PA1 and OVCAR3), lung (A549), glioblastoma (U87MG), pancreatic (MIAPaCa-2), colorectal (HCT116), cervical (Hela), melanoma (Sk-mel-28), and osteosarcoma (MG-63) cancer cell lines were purchased from NCCS cell repository, Pune.

Additionally, melanoma (ChaMel47), ovarian (SKOV3, OAW42, and UWB1.289+BRCA1), glioblastoma (U87MGvIII), and squamous oral (UPCI-SCC-084 and UPCI-SCC-131) carcinoma cell lines were kind gifts of Prof. Peter Walden, Charité-Universitätsmedizin, Berlin, Germany; Dr. SS Roy, CSIR-IICB; Dr. Frank Furnari, Ludwig Cancer Research Institute, US; Dr. Asima Mukhopadhyay, Tata Medical Center; and Dr. Susanta Roychoudhury, Saroj Gupta Cancer Center & Research Institute, Kolkata, respectively. All Cell lines were grown in complete medium ([Table 1](#tab1){ref-type="table"}) supplemented with 10% FBS and 1% antibiotic-antimycotic at 37°C, 5% CO~2~.

2.2. Collection and Drying of Plant Material {#sec2.2}
--------------------------------------------

"*Murraya koenigii* (L.) Spreng" belongs to the family Rutaceae ([http://www.theplantlist.org](http://www.theplantlist.org/)) and is widely available all over India. Plant leaflets were procured throughout the year and also from east, west, north, south, and middle parts of India for three consecutive years. These were identified by Dr. Debabrata Maity, Department of Botany, Kolkata, where a voucher specimen was deposited (20033(CUH)). These fresh leaflets (1.0 kg) were washed thoroughly with portable water followed by distilled water and dried in a dust-free environment. The dried leaflets (0.2 kg) were grinded into small pieces.

2.3. Mahanine-Enriched Fraction (MEF) {#sec2.3}
-------------------------------------

Small pieces of dried leaflets (100 gram) were kept in distilled water (2.0 liters) at 50°C for four hours with stirring occasionally. The water portion was separated by filtration, and the remaining residue was dried (75 grams) for maceration with ethanol (1.5 liters) at ∼30°C for 72 hours. This ethanolic fraction was dried. The yield of MEF from 100 g of dry leaf powder was calculated and stored at −20°C in an airtight container.

2.4. HPLC Analysis of MEF {#sec2.4}
-------------------------

For quantification of markers by HPLC (Waters, 2487, Dual *λ* Absorbance UV Detector), MEF (500 *μ*g/ml) was dissolved in methanol and water (80 : 20) and filtered using 0.22 *µ*m syringe filter. The RP-C18 column (5 *μ*m, 250 × 4.6 mm, Waters, USA) was used. Sample (200 *μ*l) was injected and run in an isocratic solvent system with 1.0 ml/minute flow rate. Peaks were monitored using a UV detector at 254 nm. All peaks area and retention time (RT, minutes) were calculated using Empower 2 software. Similarly, HPLC fingerprints of all MEFs including water extract were compared. The external calibration method was used to quantify the markers in MEF using pure compounds (5--20 *μ*g) by HPLC \[[@B10]\].

2.5. Isolation and Characterization of Markers {#sec2.5}
----------------------------------------------

MEF was packed on the silica column and eluted with petroleum ether and chloroform (100-0 : 0-100). Different fractions were monitored by TLC. Mahanine and mahanimbine fractions were separated by comparing with reference compounds which were previously isolated by our group \[[@B4]\]. Mahanine and mahanimbine were further purified by preparative TLC and HPLC using a reverse-phase C18 column to get ≥95% purity. Purification was confirmed by thin layer chromatography (TLC), high pressure liquuid chromatography (HPLC), and mass spectrometry (ESI-Q TOF instrument), and the structure was confirmed by ^1^H Nuclear magnetic resonance (NMR) and ^13^C NMR (Bruker 600 MHz and JEOL 400 MHz instruments) \[[@B4]\]. Koenimbine-containing fraction was washed thrice with methanol to yield pure compound and characterized similarly.

2.6. MTT Assay {#sec2.6}
--------------

MEF was dissolved in ethanol (10 mg/ml), and substocks were prepared with complete medium. The bioactivity of MEF, mahanine, mahanimbine, and koenimbine against cancer cell lines was determined separately by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. PA1 was harvested using trypsin and counted using the hemocytometer in the presence of trypan blue. Washed cells (4 × 10^3^ in 250 *μ*l/well) were placed in a 96-well plate and incubated for 1--2 hours. MEF (0--100 *μ*g/ml) was added to each well in triplicates and incubated for 48 h at 37°C. The medium was discarded, and MTT (dissolved in IMDM, 100 *μ*g/well) was added and incubated for 3 h at 37°C. Formazan crystals formed by the live cells were dissolved in DMSO. The intensity of the color was quantified at 550 nm in an ELISA plate reader, and IC50 values were calculated. Similarly, IC50 values were determined for all MEFs prepared from leaflets collected from various parts of India throughout the year. Additionally, IC50 values with other cell lines were also determined with MEF~TN~ (0--30 *μ*g/ml).

Mahanine/mahanimbine in absolute ethanol and koenimbine in DMSO were taken to make 5000 *μ*M stock for *in vitro* studies. Substocks were prepared with complete medium. PA1 and OVCAR3 were incubated separately with 0--100 *μ*M of purified mahanine, mahanimbine, and koenimbine for 48 h and processed similarly.

2.7. In Vivo Xenograft Mice Model {#sec2.7}
---------------------------------

MEF~TN~ (1.0 gram) was dissolved in ethanol (6.0 ml) diluted with sterile double distilled water (34 ml) to form a uniform suspension and used for oral feeding in mice. Before the initiation of the experiment, all mice were acclimated for 7 days and were kept five per group in individually ventilated cages (IVC) and used for *in vivo* efficacy studies.

Female nude mice (4--6 weeks, *n* = 10) were injected subcutaneously with PA1 and A549 cells (7 × 10^6^) separately. Tumors (∼100 mm^3^) were generated within 10--12 days. Animals were fed orally with MEF~TN~ (300 mg/kg BW) two times per day for 31 days in ovarian and 14 days in lung cancer. Control/untreated animals were fed with vehicle (15% ethanol in water). The tumor size was monitored with screw gauge. Body weight during the treatment was also measured. This study has been approved by the institute\'s ethical committee on animal experimentation.

2.8. Statistical Analysis {#sec2.8}
-------------------------

The data shown were representative of three sets of independent experiments. The results were represented as mean ± SD from independent experiments.

3. Results and Discussion {#sec3}
=========================

3.1. Enrichment of Mahanine in *M. koenigii* Extract {#sec3.1}
----------------------------------------------------

Our study for more than a decade established mahanine as a therapeutic lead molecule and may be considered as a main active principle in these leaflets. Here, we have used this carbazole alkaloid as the main stable reference marker.

However, isolation of the single molecules from the plant material is generally a multistep procedure which leads to low yield. More importantly, the majority of the plant-derived molecules are stereoisomers. The plant specifically synthesizes either levo (−) or dextro (+) isomer \[[@B11]\]. The activity of stereoisomers is not always the same; in fact, sometimes these are antagonistic \[[@B12]\]. Synthesis and purification of specific stereoisomers are difficult, time-taking, and costly process. Interestingly, plant-derived (−) mahanine is levo, which is a biologically active isomer. Even after two decades of the discovery of mahanine, the synthesis of this alkaloid is very difficult even today. Very recently, Hou et al. reported the synthesis of (±) mahanine involving eight steps with lesser yield \[[@B13]\]. This synthetic mahanine is expected to be less active as it is a mixer of two enantiomers. Therefore, isolation or synthesizing mahanine is commercially not viable.

Considering all these problems, here, we have prepared a mahanine-enriched fraction (MEF) using two edible nontoxic solvents, namely, water and ethanol, within a short time involving only two steps, which makes the final product cheaper and easy to commercialize. As mahanine is insoluble in water, clean leaflets collected from West Bengal during the September--December were extracted with hot water, and we discarded the water-soluble fraction. Next, maceration of the remaining leaflet residue with ethanol was performed. HPLC analysis of 25 *µ*g of sample demonstrated ([Figure 1(a)](#fig1){ref-type="fig"}) that the ethanolic extract after removal of water-soluble fraction exhibited enhanced mahanine content (14%) ([Table 2](#tab2){ref-type="table"}).

Each fraction was separately tested at different concentrations for its reduced metabolic activity against PA1 by the MTT assay. IC50 values were compared with the untreated control. Water extract exhibited very low/minimum activity ([Table 2](#tab2){ref-type="table"}). The ethanolic extract, after removal of inactive water-soluble fraction, exhibited more reduction in metabolic activity, IC50 being 37 *μ*g/ml. Therefore, this fraction is named as a mahanine-enriched fraction (MEF).

3.2. Isolation of Marker Compounds in MEF {#sec3.2}
-----------------------------------------

The major problem for herbal medicine is the batch to batch variations of chemical compositions which adversely influence its biological activity \[[@B14]\]. To minimize these variations, we need to have a few well-characterized chemical markers for validating HPLC fingerprinting. For this purpose, we have identified three marker molecules, namely, mahanine, mahanimbine, and koenimbine from MEF. Previously, our group reported mahanine and mahanimbine from the methanolic extract of *M. koenigii* \[[@B4]\].

Here, we have isolated the mahanine and mahanimbine using the reference compounds, and purity was confirmed by HPLC ([](#supplementary-material-1){ref-type="supplementary-material"}). ESI--MS ([](#supplementary-material-1){ref-type="supplementary-material"}), ^1^H ([](#supplementary-material-1){ref-type="supplementary-material"}), and ^13^C NMR spectral data analyses established their structures as mahanine and mahanimbine ([Figure 1(b)](#fig1){ref-type="fig"}). During this process, we have also isolated another carbazole alkaloid, koenimbine, and characterization was again confirmed by HPLC, ESI-MS, NMR, and compared with the available literature (PubChem CID: 97487). The calibration curves for all three molecules were plotted with three different concentrations (5, 10, and 20 *μ*g) for further studies ([](#supplementary-material-1){ref-type="supplementary-material"}; [](#supplementary-material-1){ref-type="supplementary-material"}).

3.3. Biological Activity of Three Carbazole Alkaloids Isolated from MEF against Ovarian Cancer Cells {#sec3.3}
----------------------------------------------------------------------------------------------------

We have earlier compared the degree of apoptosis between mahanine and mahanimbine in lymphoblastic leukemia, myeloid leukemia, glioma, pancreatic, lung, colorectal, and cervical cancers cells \[[@B4]\]. Koenimbine reduced metabolic activity of prostate cancer \[[@B15]\], breast cancer \[[@B16]\], and liver cancer cells \[[@B17]\]. However, the biological activity of mahanimbine and koenimbine was not tested in ovarian cancer cells. In our previous studies, we have tested mahanine-induced cell death by the MTT assay \[[@B8]\]. These results were corroborated with many other methods indicating reduced cell viability, i.e., apoptosis \[[@B8]\]. Therefore, reduced metabolic activity may indicate the antiproliferative property.

Here, we have compared the antiproliferative activity of all three carbazole alkaloids at different concentrations (0--100 *μ*M) both in PA1 and a cisplatin-resistant (OVCAR3) ovarian cancer cells by the MTT assay (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}). All these molecules induce cell death in a concentration-dependent manner. Mahanine exhibited the highest activity against PA1 and OVCAR3 compared to others under identical conditions ([Table 3](#tab3){ref-type="table"}).

3.4. Seasonal Variations of Mahanine {#sec3.4}
------------------------------------

Our next aim was to select the best season for collection of leaflets with a high quantity of mahanine for MEF preparation. Initially, we have collected leaflets from West Bengal for every two months throughout the year for three consecutive years. MEF was prepared (MEF~WB~) for each batch, and mahanine content was analyzed by HPLC. The highest amount of mahanine was present in leaflets collected during September to December (14 ± 1.5%), which drops to a minimum during January--April (∼5%) and medium (∼6--10%) during May--August ([Table 4](#tab4){ref-type="table"}, Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}). However, the percent of mahanimbine and koenimbine was 9--20% and 8--15%, respectively. A minimum amount of koenimbine was observed from May to July. A similar trend was observed in three years.

The IC50 of all MEFs was tested with different concentrations and compared against PA1 ([Table 4](#tab4){ref-type="table"}). The IC50 of MEF from the leaflets collected during September--December was highest corroborating with a higher content of mahanine suggesting the best time for collection.

3.5. Variation of Mahanine in the Leaflets Collected from Different Geographical Locations {#sec3.5}
------------------------------------------------------------------------------------------

Chemical composition/active principle of the plant varies from place to place in a wide range from 0.9 to 100 \[[@B18]\]. The medicinal value of a plant is directly proportional to the quantity of biologically active principles. Mahanine is the most active carbazole alkaloid found in *M. koenigii*.

To standardize the place, we have collected leaflets from nine different regions covering all parts of India from September to December in three consecutive years. The plant material was authenticated by DNA bar-coding as reported earlier \[[@B19]\]. Leaflets of different regions varied in their shape, size, thickness, color (dark/light green), and odor ([Figure 4(a)](#fig4){ref-type="fig"}). The yield (gram of MEF/100 g of the dry leaf) varied from 5.5% to 9.0%, Tamil Nadu being the highest. Interestingly, the percent of mahanine varied in a wide range from ∼2.7 to 43% ([Table 5](#tab5){ref-type="table"}). The amount of mahanine (Figures [4(b)](#fig4){ref-type="fig"} and [4(c)](#fig4){ref-type="fig"}) is highest in Tamil Nadu (MEF~TN~; ∼43 ± 2.5%), and Bihar leaflets exhibited the lowest quantity (MEF~B~; 2.7 ± 1.3%). However, the percent of mahanimbine (∼8.3%) and koenimbine (∼0.8%) in MEF~TN~ was significantly low. The percent of these two alkaloids differs from place to place. In most of the places, the percent of koenimbine is either low or sometimes not even detectable. HPLC fingerprint of MEF, prepared from all these leaflets, is also different ([Figure 5](#fig5){ref-type="fig"}). The percent of alkaloids present in the leaflets collected during three years did not vary significantly.

The content of mahanimbine is inversely proportionally to the mahanine in the majority of the places, Jammu (MEF~J~) being the highest. It is worthwhile to mention that these two molecules just differed with a hydroxyl group (-OH) at C7 position. We have earlier demonstrated the structure-activity relationship of these two alkaloids and confirmed that -OH group is crucial for its antiproliferative effect against cancer cells \[[@B4]\].

The highest yield of MEF and amount of mahanine in these leaflets depends on various factors including temperature, rainfall, and sunshine in this Torrid Zone. In summary, the best place for collecting leaflets with the highest quantity of mahanine is southern part (tropical zone), Tamil Nadu (MEF~TN~). Our data proved that selection of the place for collection of plant material is an essential component for preparing any extract/fraction with the highest medicinal property.

3.6. Correlation of Mahanine Content and Antiproliferative Activity of MEFs {#sec3.6}
---------------------------------------------------------------------------

The MEF prepared from leaflets collected from different regions of India during September--December was checked for their biological activity against PA1 with various concentrations. IC50 varied from ∼15 to ∼75 *μ*g/ml, indicating ∼5 fold reduced biological activity of MEF~TN~ compared to MEF~B~ corroborating with the highest percent of mahanine ([Figure 4(d)](#fig4){ref-type="fig"}).

Statistical evaluation of these results by the "Spearman-rank" correlation method showed 0.97 (97.6%) which confirms the significance of the positive correlation between mahanine content in the leaflets and its biological activity against cancer cells. Therefore, the medicinal values of the plant are directly proportional to the mahanine content.

Although other two markers (mahanimbine and koenimbine) showed reduced metabolic activity separately, they present in minute amount, respectively, in MEF~TN~ ([Table 5](#tab5){ref-type="table"}) is compared to biologically more active mahanine (∼43%). Due to the low concentration of mahanimbine and koenimbine, they may not contribute significantly to the total activity of MEF~TN~.

Since mahanine content is more in MEF~TN~; next, we have compared the percent of this alkaloid in the leaflets collected from ten different regions within the Tamil Nadu during different seasons. As expected, mahanine content is more from September to December. Leaflets from all ten places showed a good amount of mahanine varying from 35 to 45%. IC50 of MEF from these leaflets was in the range of 15--20 *μ*g/ml. Here, also we confirmed that the activity of MEF depends upon the percent of the mahanine present in these leaflets.

3.7. In Vitro Activity of MEF against Various Cancer Cell Lines of Different Origins {#sec3.7}
------------------------------------------------------------------------------------

So far, our results demonstrated that both the mahanine content and biological activity are highest in MEF~TN~. Next, this (0--60 *μ*g/ml) was tested against sixteen cancer cell lines with different mutations and chemoresistant status belonging to nine different cancers. MEF reduced the metabolic activity in all these cell lines in a concentration-dependent manner. IC50 values were in the range of ∼13.2--19.0 *μ*g/ml in ovarian, lung, Grade IV glioblastoma, melanoma, pancreatic, colorectal, cervical, osteosarcoma, and oral cancers ([Table 1](#tab1){ref-type="table"}). MEF~TN~ (0--150 *μ*g/ml) was tested against normal lung fibroblast cells, IC50 being ∼80 *μ*g/ml. This result demonstrates the potentiality of MEF as a broad antiproliferative agent in many different cancers with various mutations at low concentration.

Additionally, we observed that except OVCAR3 and UWB1.289+BRCA1, all other cells exhibited IC50 \< 20 *μ*g/ml of MEF~TN~. OVCAR3 cells are reported to be resistant to cisplatin, Adriamycin, and melphalan \[[@B20]\]. UWB1.289+BRCA1 cells having BRCA1 mutation is resistant to PARP inhibitor drugs like rucaparib, olaparib, and veliparib \[[@B21]\]. Due to these inherent drug-resistance properties, these two cell lines showed higher IC50 values compared to others.

3.8. Efficacy of MEF~TN~ in Ovarian and Lung Cancer Xenograft Models {#sec3.8}
--------------------------------------------------------------------

To check the *in vivo* efficacy of MEF~TN~, we have used two representative ovarian and lung cancers models. MEF~TN~-treated mice (300 mg/kg BW *p.o.* BID) showed reduction in tumor size from ∼354 to 89 mm^3^ in ovarian cancer compared to the untreated animals (Figures [6(a)](#fig6){ref-type="fig"} and [6(b)](#fig6){ref-type="fig"} and [Table 6](#tab6){ref-type="table"}). No weight loss was observed in MEF-treated tumor-bearing mice up to 31 days indicating no apparent toxicity in other organs ([Figure 6(c)](#fig6){ref-type="fig"}). Similarly, MEF~TN~-treated animal exhibited a reduced tumor mass from ∼426 to 170 mm^3^ in lung cancer model (Figures [6(d)](#fig6){ref-type="fig"} and [6(e)](#fig6){ref-type="fig"}).

4. Conclusions {#sec4}
==============

We are reporting a mahanine-enriched fraction (MEF) prepared using two nontoxic edible solvents in two steps. Three carbazole alkaloids, namely, mahanine, mahanimbine, and koenimbine, have been isolated and characterized. This is the first report showing reduced metabolic activity of mahanimbine and koenimbine in ovarian cancer cells in a concentration-dependent manner. Our systematic study ([Figure 7](#fig7){ref-type="fig"}) reveals that the percent of mahanine is highest in leaflets collected from Tamil Nadu (MEF~TN~) from September to December. MEF~TN~ exhibited the highest activity against cancer cells. Thus, the medicinal values of this plant are directly proportional to the amount of mahanine present in the leaflets. Most importantly, MEF~TN~ significantly reduces tumor mass both in ovarian and lung cancer xenograft models. Taken together, this study suggests that we can improve the medicinal property of this high-value plant to ∼5 fold by right selection of season and place for leaf collection. MEF~TN~ also showed reduced metabolic activity in sixteen cells lines from nine different origins in a concentration-dependent manner. To the best of our knowledge, this is the first report demonstrating variations of mahanine, mahanimbine, and koenimbine in this important herb collected during different seasons from various locations of India reflected in their medicinal values. Such a study is expected to increase the commercial values of this medicinal plant and enhance the efficacy of phytopharmaceuticals prepared from this herb.
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OC:

:   Ovarian cancer

MEF:

:   Mahanine-enriched fraction

MEF~WB~:

:   MEF from West Bengal leaflets

MEF~TN~:

:   MEF from Tamil Nadu leaflets

MEF~B~:

:   MEF from Bihar leaflets

IC50:

:   The half-maximal inhibitory concentration

BW:

:   Bodyweight

MTT:

:   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

FBS:

:   Fetal bovine serum

*p.o.*:

:   Per os (oral administration)

BID:

:   Bis in die (twice daily).
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Figure S1: (HPLC analysis) the purity of three markers isolated from MEF and the retention time (RT) was confirmed by HPLC. Mahanine, mahanimbine, and koenimbine were dissolved in running solvent (methanol : water, 80 : 20) and filtered through 0.22 *μ*m and injected into the HPLC rheodyne injector. All the three markers were found to be pure (≥95%), and RT matched with reference compounds. Figure S2: Determination of molecular weights by electrospray ionization-mass spectrometry (ESI-MS); ESI-MS revealed that the molecular weight of mahanine (M + Na = 370.13) is 347.45, mahanimbine (M + 1 = 332.30) is 331.45, and koenimbine (M + 1 = 294.32) is 293.36. Figure S3: Confirmation of molecular structures of mahanine, mahanimbine, and koenimbine by ^1^H NMR. Mahanine: ^1^H NMR (400 MHz, Methanol-*d*~4~) *δ* 7.62 (d, *J* = 7.7 Hz), 7.52, 7.45, 6.77, 6.58, 5.64--5.57 (m), 5.08, 3.28, 2.24, 2.12 (d, *J* = 6.2 Hz), 1.67 (d, *J* = 9.5 Hz), 1.60, 1.53, 1.37. Mahanimbine: ^1^H NMR (600 MHz, chloroform-*d*) *δ* 7.89 (d, *J* = 6.0 Hz, 1H), 7.82 (s, 1H), 7.64 (s, 1H), 7.31--7.26 (m, 2H), 7.16 (ddd, *J* = 6.0 Hz, 1H), 6.54 (d, *J* = 6.0 Hz, 1H), 5.58 (d, *J* = 6.0 Hz, 1H), 5.10 (ddt, *J* = 6.0 Hz, 1H), 2.32 (d, *J* = 6.0 Hz, 3H), 2.23--2.10 (m, 3H), 1.74 (dd, *J* = 9.3, 7.4 Hz, 2H), 1.65 (d, *J* = 1.7 Hz, 3H), 1.57 (d, *J* = 1.6 Hz, 3H), 1.42 (s, 3H). Koenimbine: ^1^H NMR (600 MHz, chloroform-*d*) *δ* 7.72 (s, 1H), 7.62 (s, 1H), 7.40 (d, *J* = 2.5 Hz, 1H), 7.25 (d, *J* = 1.3 Hz, 1H), 6.93 (dd, *J* = 8.7, 2.5 Hz, 1H), 6.57 (d, *J* = 9.7 Hz, 1H), 5.66 (d, *J* = 9.7 Hz, 1H), 3.90 (s, 3H), 2.32 (d, *J* = 0.9 Hz, 3H), 1.48 (s, 6H). All these NMR\'s were matched with the available literature (PubChem CID: 375151, 167963, and 97487, respectively). Figure S4: (calibration curves of mahanine, mahanimbine, and koenimbine) all three carbazole alkaloids were dissolved separately in methanol : water (80 : 20) and filtered for HPLC analysis. Each molecule was injected separately in three different concentrations (5, 10, and 20 *μ*g). Area vs. concentration was plotted. This calibration curve was used to calculate the amount of these markers in different MEFs. Table S1: the obtained area of each concentration for the respective molecule from Figure S4 was tabulated to calculate the amount of all three markers in different MEF\'s.
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![(a) HPLC profile of MEF~WB~ and structures of identified markers. The arrows indicate the peaks corresponding to the three isolated markers matched with their retention times in the HPLC profile of MEF~WB~. (b) Chemical structures of three carbazole alkaloids isolated from MEF~WB~ used as markers.](BMRI2020-7821913.001){#fig1}

![Antiproliferative activities of mahanine, mahanimbine, and koenimbine isolated from MEF~WB~ against ovarian cancer as determined by the MTT assay (a, b). Ovarian cancers cells were exposed to varying concentrations of purified mahanine, mahanimbine, and koenimbine separately for 48 h. IC50 was calculated as the percentage relative to untreated cells which were considered as 100%. Antiproliferative activity of mahanine against PA1 and OVCAR3 by MTT assay has earlier been reported \[[@B8]\]; here, we have repeated this experiment for comparison with mahanimbine and koenimbine. These data were derived from three individual experiments, and mean ± SD was indicated.](BMRI2020-7821913.002){#fig2}

![Seasonal variation of mahanine in MEF~WB~. (a) MEF~WB~ prepared from the leaflets collected during different seasons was analyzed by HPLC. The variations in percent of mahanine were plotted on the graph. (b) Schematic representation of seasonal variations of mahanine from low to high. These data were derived from three individual experiments, and mean ± SD was indicated.](BMRI2020-7821913.003){#fig3}

![Geographical variations of mahanine, mahanimbine, and koenimbine and its relation with antiproliferative activity. (a) Morphological differences in leaflets collected from nine different locations. (b) Locations for leaflets collection were marked on the map; highlights with black, green, and red dots represent the low, medium, and high quantities of mahanine. (c) The percent of mahanine in MEFs prepared from different places. (d) IC50 values of MEFs were checked for their activity against PA1 for 48 h by the MTT assay. These results were compared with mahanine quantity as depicted in [Figure 4(d)](#fig4){ref-type="fig"}. These data were derived from three individual experiments, and mean ± SD was indicated.](BMRI2020-7821913.004){#fig4}

![HPLC fingerprints all MEFs, showing the geographical variations of three markers. HPLC profiles of MEFs from leaflets were marked for mahanine, mahanimbine, and koenimbine with their respective retention times (RTs) for comparison.](BMRI2020-7821913.005){#fig5}

![Activity of MEF~TN~ in ovarian and lung cancer xenograft model in nude mice. (a, d) Ovarian cancer and lung cancer models were generated in nude mice using PA1 and A549 cell lines, respectively. Representative images of both the tumors were presented. (b, e) MEF~TN~ was fed orally and tumor size was compared with untreated tumor-bearing mice. (c) Body weights were monitored and plotted. ^*∗*^Significant difference at *p* \< 0.05.](BMRI2020-7821913.006){#fig6}

![Summary of the study. This figure shows the workflow and conclusions of the study. These data were derived from three individual experiments, and mean ± SD was indicated. ^*∗*^The significant difference of *p* \< 0.05.](BMRI2020-7821913.007){#fig7}

###### 

Biological activity of MEF~TN~.

  S. No.   Cancer type                    Cell lines                     Mutation/drug-resistant              Culturing media + 10% FBS   MEF~TN~ IC50 (*μ*g/ml)
  -------- ------------------------------ ------------------------------ ------------------------------------ --------------------------- ------------------------
  1        Ovarian                        PA1                            NRAS mutation anoikis-resistant      MEM                         15 ± 0.2
  2        OVCAR3                         TP53 mutation drug-resistant   RPMI 1640                            27 ± 0.18                   
  3        SKOV3                          TP53 mutation                  McCoy\'s 5a                          16.5 ± 0.11                 
  4        OAW42                          ARID1A, PIK3CA mutation        DMEM                                 15.5 ± 0.05                 
  5        UWB1.289 + BRCA1               BRCA1 mutation                 MEBM + RPMI 1640 (1 : 1)             25 ± 0.2                    
                                                                                                                                          
  6        Lung carcinoma                 A549                           KRAS, CDKN2A mutation                IMDM                        13.0 ± 0.09
                                                                                                                                          
  7        Grade IV glioblastoma          U-87 MG                        PTEN mutation                        IMDM                        16.2 ± 0.15
  8        U87MG vIII                     EGFR mutation                  IMDM                                 18.7 ± 0.02                 
                                                                                                                                          
  9        Pancreatic carcinoma           MIA PaCa-2                     TP53, K-RAS mutation, p16 deletion   RPMI-1640                   14.1 ± 0.1
                                                                                                                                          
  10       Colorectal                     HCT116                         KRAS, PIK3CA mutation                IMDM                        13.4 ± 0.4
                                                                                                                                          
  11       Cervical                       Hela                           STK11, CTNNB1, CNTN1 mutations       IMDM                        15.45 ± 0.05
                                                                                                                                          
  12       Squamous cell oral carcinoma   UPCI-SCC084                    TP53 mutation                        DMEM                        14.5 ± 0.25
  13       UPCI-SCC131                    TP53 wild type                 DMEM                                 15.5 ± 0.25                 
                                                                                                                                          
  14       Osteosarcoma                   MG63                           CDKN2A mutation                      MEM                         14.9 ± 0.22
                                                                                                                                          
  15       Melanoma                       ChaMel47                       No reports on mutation               IMDM                        18.5 ± 0.21
  16       Sk-mel-28                      B-RAF, TP53 mutation           RPMI 1640                            19 ± 0.11                   
                                                                                                                                          
  17       Normal lung fibroblast cells   WI-38                          ---                                  MEM                         \>80 ± 0.8

Antiproliferative activity of mahanine-enriched fraction prepared from Tamil Nadu leaflets (MEF~TN~) was analyzed by the MTT assay. IC50 values and mutation status of all cancers cell lines were tabulated. These data were derived from three individual experiments, and mean ± SD was indicated.

###### 

Preparation of MEF form *M. koenigii* leaflets from West Bengal.

  Extract                                Mahanine (%)   IC50 (*μ*g/ml)
  -------------------------------------- -------------- ----------------
  Water extract                          0              90
  Mahanine-enriched fraction (MEF~WB~)   14             37

Comparison of the water extract and MEF~WB~ for their mahanine content and biological activity against PA1. IC50: the half-maximal inhibitory concentration.

###### 

Reduced metabolic activity by three carbazole alkaloids from MEF against ovarian cancer.

  Ovarian cancer cell lines   IC50 (*μ*M)               
  --------------------------- ------------- ----------- -----------
  PA1                         11 ± 0.2      28 ± 0.11   51 ± 0.25
  OVCAR3                      32 ± 0.18     52 ± 0.05   68 ± 0.22

Cells were treated separately with mahanimbine and koenimbine for 48 h, and mahanine was used as the control for comparison \[[@B8]\]. IC50 values were compared. These data were derived from three individual experiments, and mean ± SD was indicated.

###### 

Seasonal variation of three markers and antiproliferative activity of MEF~WB~.

  The month of collection of leaflets   Mahanine (%)   Mahanimbine (%)   Koenimbine (%)   MEF~WB~ IC50 (*μ*g/ml)
  ------------------------------------- -------------- ----------------- ---------------- ------------------------
  February                              5 ± 1.5        12 ± 1.4          15 ± 1.8         73.2 ± 0.15
  April                                 5 ± 1.9        11 ± 1.8          12 ± 1.2         71.0 ± 0.5
  May                                   6 ± 1.7        9 ± 1.5           8 ± 0.9          68.0 ± 0.14
  July                                  9 ± 1.6        16 ± 1.2          8 ± 1.5          55.0 ± 0.3
  September                             12 ± 1.8       18 ± 1.6          10 ± 1.1         39.0 ± 0.3
  December                              14 ± 1.5       20 ± 1.6          11 ± 1.25        37.0 ± 0.2

Composition of markers in MEF~WB~ in different seasons and their IC50. These are representative data collected in one year. MEF~WB~: mahanine-enriched fraction prepared from West Bengal leaflets. These data were derived from three individual experiments, and mean ± SD was indicated.

###### 

Regional variation of mahanine, mahanimbine, and koenimbine in different MEFs.

  Region of leaf collection   Yield: a gram of MEF/100 g of dry leaf   Mahanine (%)   Mahanimbine (%)   Koenimbine (%)
  --------------------------- ---------------------------------------- -------------- ----------------- ----------------
  Jammu (MEF~J~)              6.4 ± 0.5                                9.3 ± 1.6      27.0 ± 2.5        6.3 ± 1.2
  Bihar (MEF~B~)              5.8 ± 0.2                                2.7 ± 1.3      12.0 ± 1.5        7.3 ± 1.4
  Madhya Pradesh (MEF~MP~)    7.2 ± 0.1                                5.0 ± 0.9      8.6 ± 0.9         1.2 ± 0.9
  West Bengal (MEF~WB~)       5.5 ± 0.5                                14.0 ± 0.8     20.7 ± 1.2        11.9 ± 1.1
  Goa (MEF~G~)                6.5 ± 0.6                                33.0 ± 2.9     6.3 ± 0.9         ND
  Maharashtra (MEF~M~)        5.9 ± 0.1                                34.0 ± 2.7     10.0 ± 1.1        ND
  Andhra Pradesh (MEF~AP~)    5.9 ± 0.25                               23.0 ± 4.1     9.2 ± 0.9         ND
  Tamil Nadu (MEF~TN~)        9.0 ± 0.7                                43.0 ± 2.5     8.3 ± 1.7         0.8 ± 0.3
  Kerala (MEF~K~)             8.0 ± 0.5                                35 ± 4.0       6.3 ± 1.2         ND

The yield of all MEFs (mahanine-enriched fractions) and their markers as obtained from HPLC. ND: not detected. A representative profile of these alkaloids in leaflet collected during one year has been tabulated. These data were derived from three individual experiments, and mean ± SD was indicated.

###### 

*In vivo* efficacy of MEF~TN~ in tumor xenograft models.

  Groups      Ovarian (PA1)   Lung (A549)
  ----------- --------------- -------------
  Untreated   354 ± 7.1       426 ± 60
  MEF~TN~     89 ± 15         170 ± 43

Xenograft models were generated in nude mice. MEF~TN~ (300 mg/kg BW *p.o.* BID) was fed orally in treated groups, and vehicle was fed to the untreated group for 31 days in ovarian and 14 days in lung cancer. Mean ± SD was indicated in the result.
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